Prenetics Group (PRE) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Prenetics Global Limited reported a remarkable 59.4% revenue growth in the third quarter of 2024, reaching $7.8 million, fueled by the successful launch of its new premium supplements brand, IM8Health.com, and strategic expansion in the U.S. market. Additionally, Tencent’s $30 million investment in Prenetics’ early cancer detection venture, Insighta, underscores investor confidence in the company’s innovative health solutions. With a strengthened financial position and ambitious revenue targets, Prenetics is poised for continued growth in the health sciences sector.
For further insights into PRE stock, check out TipRanks’ Stock Analysis page.
